Corcept Therapeutics (NASDAQ:CORT) Receives “Buy” Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) in a report issued on Friday morning,Benzinga reports. The firm currently has a $80.00 target price on the biotechnology company’s stock. A number of other brokerages have also commented on CORT. StockNews.com lowered shares of Corcept Therapeutics from a “strong-buy” […]
HC Wainwright reiterated their buy rating on shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) in a report issued on Friday morning,Benzinga reports. The firm currently has a $80.00 target price on the biotechnology company’s stock. A number of other brokerages have also commented on CORT. StockNews.com lowered shares of Corcept Therapeutics from a “strong-buy” […]
